Acinetobacter baumannii nosocomial infections

Polski Przeglad Chirurgiczny/ Polish Journal of Surgery

Volumn 85, Issue 9, 2013, Pages 483-490

  Sieniawski, Karol ^a   Kaczka, Krzysztof ^a   Rucinska, Monika ^a   Gagis, Ludmila ^b   Pomorski, Lech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Memorial M Sklodowska Curie Hospital in Zgierz   (Poland)

Author keywords

Acinetobacter baumannii; Multidrug resistant; Nosocomial infections

Indexed keywords

ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; CLASSIFICATION; CROSS INFECTION; DRUG EFFECTS; HUMAN; MULTIDRUG RESISTANCE; POLAND; PREVALENCE; SPECIES DIFFERENCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; POLAND; PREVALENCE; SPECIES SPECIFICITY;

EID: 84888881780     PISSN: 0032373X     EISSN: None     Source Type: Journal    
DOI: 10.2478/pjs-2013-0075     Document Type: Article

References (30)

1. Karlowsky JA, Draghi DC, Jones ME et al.: Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001 Antimicrobial Agents and Chemotherapy 2003: 47; 1681-87.
2. Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: Emergence of a successful pathogen. Clinical Microbiology Reviews 2008; 21: 538-82.
3. Lee K, Yong D, Jeong SH et al.: Multidrug-Resistant Acinetobacter spp.: Increasingly Problematic Nosocomial Pathogens Yonsei. Medical J 2011; 52: 879-91.
4. Jawad A, Seifert H, Snelling AM et al.: Survival of Acinetobacter baumannii on dry surfaces: Comparison of outbreak and sporadic isolates. J Clinical Microbiol 1998; 36: 1938-41.
5. Wendt C, Dietze B, Dietz E et al.: Survival of Acinetobacter baumannii on dry surfaces. J Clinical Microbiol 1997; 35: 1394-97.
6. Marti S, Chabane YN, Alexandre S et al.: Growth of Acinetobacter baumannii in Pellicle Enhanced the Expression of Potential Virulence Factors Plos One 2011; 6.
7. Husni RN, Goldstein LS, Arroliga AC et al.: Risk factors for an outbreak of multi-drug-resistant acinetobacter nosocomial pneumonia among intubated patients. Chest 1999; 115: 1378-82.
8. Falagas ME, Bliziotis IA, Siempos II : Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Critical Care 2006; 10.
9. Falagas ME, Rafailidis PI: Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Critical Care 2007; 11.
10. Falagas ME, Koletsi PK, Bliziotis IA : The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Medical Microbiol 2006; 55: 1619-29.
11. O'Shea MK: Acinetobacter in modern warfare. International J Antimicrobiol Agents 2012; 39: 363-75.
12. Kempf M, Rolain JM: Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. International J Antimicrobiol Agents 2012; 39: 105-14.
13. BergogneBerezin E, Towner KJ: Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clinical Microbiol Reviews 1996; 9: 147.
14. Unal S, Garcia-Rodriguez JA: Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagnostic Microbiol and Infectious Dis 2005; 53: 265-71.
15. Mera RM, Miller LA, Amrine-Madsen H et al.: Acinetobacter baumannii 2002-2008: Increase of Carbapenem-Associated Multiclass Resistance in the United States Microbial Drug Resistance 2010; 16: 209-15.
16. Queenan AM, Pillar CM, Deane J et al.: Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diag Microbiol and Infectious Dis 2012; 73: 267-70.
17. Li C, Kuti JL, Nightingale CH et al.: Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clinical Pharmacol 2006; 46: 1171-77.
18. Jaruratanasirikul S, Sriwiriyajan S, Punyo J: Comparison of the pharmacodynamics of meropenem in patients with ventilator-Associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents and Chemother 2005; 49: 1337-39.
19. Kipnis E, Guery BP: Colistin revisited. Antibiotiques 2010; 12: 205-27.
20. Michalopoulos AS, Falagas ME: Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011; 1: 30.
21. Hancock REW, Chapple DS: Peptide antibiotics. Antimicrob Agents and Chemother 1999; 43: 1317-23.
22. Landman D, Georgescu C, Martin DA et al.: Polymyxins revisited. Clinical Microbiol Reviews 2008; 21: 449-65.
23. Kalin G, Alp E, Coskun R et al.: Use of highdose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii39. ventilator-Associated pneumonia: do we really need this treatment? J Infection and Chemother 2012; 18: 872-77.
24. Livermore DM, Hill RLR, Thomson H et al.: Antimicrobial treatment and clinical outcome for infections with carbapenem-And multiply-resistant Acinetobacter baumannii around London. International J Antimicrobial Agents 2010; 35: 19-24.
25. Brauers J, Frank U, Kresken M et al.: Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clinical Microbiol and Infection 2005; 11: 24-30.
26. Bantar C, Fernandez Canigia L, Alejandra Berger M et al.: Pharmacodynamic Assessment of Amoxicillin-Sulbactam Against Acinetobacter baumannii: Searching the Optimal Dose and Infusion Time Through a Human ex-vivo Model. Brazilian J Infectious Dis 2009; 13: 348-52.
27. Deveci A, Coban AY, Acicbe O et al.: In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J Chemother 2012; 24: 247-52.
28. Patzer J, Dzierzanowska D, Turner P: Susceptibility patterns of Gram-negative bacteria from a Polish intensive care unit, 1997-2000. International J Antimicrob Agents 2002; 19: 431-34.
29. Eckmann C, Heizmann WR, Leitner E et al.: Prospective, Non-Interventional, Multi-Centre Trial of Tigecycline in the Treatment of Severely Ill Patients with Complicated Infections -New Insights into Clinical Results and Treatment Practice Chemotherapy 2011; 57: 275-84.
30. Ricciardi R, Ricciardi AM, Danzi G: In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates Le infezioni in medicina: rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 2009; 17: 236-39.